Concomitative results showed that RET-TKIs treatment was significantly effective in RET fusion-positive NSCLC patients, with ORR of 67% (95%CI: 0.64–0.70) and DCR of 92% (95%CI: 0.91–0.94), respectively. Here, RET is linked to non-small cell lung carcinoma.